Gapping up:
In reaction to strong earnings/guidance: HK +16% (light volume), RHT +6.4%, BBRY +5.8%, DRI +2.9%, AIR +2.7% (light volume), CNC +2.6% (ticking higher), LEN +1.7%, DLTH +0.8%.
M&A news: QIHU +2.8% (enters into a definitive merger agreement to be acquired by a consortium of investors in an all-cash transaction valued at ~$9.3 bln, or $77.00/share), .
Metals/mining stocks trading higher: HMY +11.8%, SBGL +5.9%, AU +2.3%, ABX +2.3%, BHP +2% (also higher despite Moody's placing ratings of BHP Billiton on review for downgrade), MT +1.9% (also higher despite downgraded to Sector Perform at RBC Capital Mkts), RIO +1.7%, GDX +1.2%, SLV +0.9%, GLD +0.7%
In reaction to strong earnings/guidance: HK +16% (light volume), RHT +6.4%, BBRY +5.8%, DRI +2.9%, AIR +2.7% (light volume), CNC +2.6% (ticking higher), LEN +1.7%, DLTH +0.8%.
M&A news: QIHU +2.8% (enters into a definitive merger agreement to be acquired by a consortium of investors in an all-cash transaction valued at ~$9.3 bln, or $77.00/share), .
Metals/mining stocks trading higher: HMY +11.8%, SBGL +5.9%, AU +2.3%, ABX +2.3%, BHP +2% (also higher despite Moody's placing ratings of BHP Billiton on review for downgrade), MT +1.9% (also higher despite downgraded to Sector Perform at RBC Capital Mkts), RIO +1.7%, GDX +1.2%, SLV +0.9%, GLD +0.7%
Other news: GPT +16.2% (Gramercy Property Trust and Chambers Street Properties close merger, complete private placement of $150 mln in senior unsecured notes, enter into new credit facility; initiated with a Buy at DA Davidson), GALE +4.1% (light volume, Galena Biopharma agress to sell Zuplenz to Midatech Pharma (MTP) for an upfront payment of $3.75 mln), BTU +6.8% (issues update, discloses potential plan to raise $150 mln in debt financing as well as a new $250 mln credit facility), JRJC +4.6% (announced that it has received ~$24.0 million from its investment in the Langfang real estate project, including fully recovered principal of ~$21.7 million.), TK +3.2% (following ~60% decline yesterday), NSPH +3.1% (prices $10 mln public offering of common stock at $0.47/share), CDXS+2.9% (ticking higher, announces multi-year contract extension to supply MSD with enzyme used in manufacture of Sitagliptin), RMBS +2.7% (to collaborate with Microsoft researchers in the exploration of future memory requirements for quantum computing), GMLP +2.5% (following ~30%+ decline yesterday), PTLA +1% (ticking higher, announces completion of BLA submission to FDA for Andexanet Alfa).
Analyst comments: ROSG +4.8% (initiated with a Spec. Buy at Cantor Fitzgerald -- Thyroid may reveal ROSG to be your CUP of Tea), PLUG +3.2% (initiated with a Outperform at FBR Capital), SUNE +2.4% (initiated with a Outperform at FBR Capital; tgt $10.50), DERM +1.7% (upgraded to Buy from Neutral at Citigroup), FIT +1.4% (initiated with a Buy at Mizuho), DD +0.9% (upgraded to Buy at BofA/Merrill),CRM +0.7% (upgraded to Outperform from Neutral at Wedbush), EXAS +0.7% (initiated with a Buy at BTIG Research)
Analyst comments: ROSG +4.8% (initiated with a Spec. Buy at Cantor Fitzgerald -- Thyroid may reveal ROSG to be your CUP of Tea), PLUG +3.2% (initiated with a Outperform at FBR Capital), SUNE +2.4% (initiated with a Outperform at FBR Capital; tgt $10.50), DERM +1.7% (upgraded to Buy from Neutral at Citigroup), FIT +1.4% (initiated with a Buy at Mizuho), DD +0.9% (upgraded to Buy at BofA/Merrill),CRM +0.7% (upgraded to Outperform from Neutral at Wedbush), EXAS +0.7% (initiated with a Buy at BTIG Research)